In human cancer, overexpression of LGR5 has been noted in up to 90% of hepatocellular carcinomas with β-catenin mutations [61] and in a large proportion of colorectal carcinomas [34], [35], [60], where APC mutations and hence dysregulated wnt signalling are preponderant. The gene discussed is LGR5; the disease is cancer.